for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Sanofi SA (ADR)

SNY.OQ

Latest Trade

52.44USD

Change

0.37(+0.71%)

Volume

368,083

Today's Range

52.13

 - 

52.65

52 Week Range

37.62

 - 

55.00

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
52.07
Open
52.59
Volume
368,083
3M AVG Volume
20.69
Today's High
52.65
Today's Low
52.13
52 Week High
55.00
52 Week Low
37.62
Shares Out (MIL)
1,253.60
Market Cap (MIL)
131,904.30
Forward P/E
15.29
Dividend (Yield %)
3.24

Next Event

Sanofi SA at Sanford C Bernstein Strategic Decisions Conference (Virtual)

Latest Developments

More

Sanofi Partners With Health2Sync In Taiwan

Sanofi: FDA grants Dupixent® (dupilumab) Breakthrough Therapy designation for eosinophilic esophagitis

Regeneron Says FDA Grants Dupixent Breakthrough Therapy Designation For Eosinophilic Esophagitis

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Sanofi SA (ADR)

Sanofi is a healthcare company, focused on patient needs and engaged in the research, development, manufacture and marketing of therapeutic solutions. Its segments are Pharmaceuticals, Human Vaccines (Vaccines), and Other. The Pharmaceuticals segment comprises the commercial operations of various franchises, including Speciality Care (Rare Diseases, Multiple Sclerosis, and Oncology), Diabetes and Cardiovascular, Established Prescription Products, Consumer Healthcare and Generics, and research and development, production and marketing activities for all of the Company's pharmaceuticals operations. The Vaccines segment is dedicated to vaccines and includes the commercial operations of the Company's vaccines division Sanofi Pasteur and dedicated research and development, production and marketing activities for the Company's vaccines operations. Its Rare Diseases products include Cerezyme, Cerdelga, Myozyme and Lumizyme, Fabrazyme, and Aldurazyme. It partners with Alnylam Pharmaceuticals.

Industry

Biotechnology & Drugs

Contact Info

54 rue la Boetie

75008

France

+33.1.53774000

https://www.sanofi.com/

Executive Leadership

Serge Weinberg

Independent Chairman of the Board

Paul Hudson

Chief Executive Officer, Member of the Executive Committee, Director

Jean-Baptiste Chasseloup de Chatillon

Chief Financial Officer, Executive Vice President, Member of the Executive Committee

Karen Linehan

Executive Vice President - Legal Affairs and General Counsel, Member of the Executive Committee

Caroline Luscombe

Executive Vice President of Human Resources, Member of the Executive Committee

Key Stats

1.40 mean rating - 5 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2017

39.5K

2018

40.7K

2019

40.4K

2020(E)

43.6K
EPS (USD)

2017

3.123

2018

3.226

2019

3.352

2020(E)

3.430
Price To Earnings (TTM)
10.01
Price To Sales (TTM)
2.96
Price To Book (MRQ)
1.75
Price To Cash Flow (TTM)
8.85
Total Debt To Equity (MRQ)
39.42
LT Debt To Equity (MRQ)
33.77
Return on Investment (TTM)
11.36
Return on Equity (TTM)
9.44

Latest News

Latest News

Latest on the worldwide spread of coronavirus

European countries from Denmark to Greece have announced new restrictions to curb surging coronavirus infections in some of their largest cities, while Britain is considering new measures to tackle an "inevitable" second wave of COVID-19.

EU pays $384 million for Sanofi-GSK COVID vaccine as WHO scheme deadline looms

The European Union has agreed to buy a potential COVID-19 vaccine from Sanofi and GSK in its second such deal to secure supplies, as a deadline for joining the World Health Organization's (WHO) vaccine purchase programme looms.

Roche studies Ocrevus, experimental drug in bid to defend MS franchise

Roche aims to defend its multiple sclerosis (MS) franchise from rivals Novartis and Sanofi with new studies of its $4 billion-per-year Ocrevus product and advanced trials of an experimental medicine, fenebrutinib.

Sanofi France chief sees coronavirus vaccine priced below 10 euros

A coronavirus vaccine that Sanofi <SASY.PA> is developing with Britain's GlaxoSmithKline <GSK.L> is likely to be priced at less than 10 euros ($11.80) per shot if it is approved for use, Sanofi's chief in France said on Saturday.

Sanofi France chief: future COVID-19 vaccine seen below 10 euros

Sanofi's chief in France, Olivier Bogillot, said on Saturday that its future COVID-19 vaccine was likely to be priced below 10 euros per shot.

Sanofi, GSK launch trial for COVID-19 protein-based vaccine

French drugmaker Sanofi and Britain's GlaxoSmithKline said they had started a clinical trial of their protein-based COVID-19 vaccine candidate, and aimed to reach the final testing stage by December.

Sanofi and GSK launch trial for COVID-19 protein-based vaccine

French drugmaker Sanofi and its British peer GSK have started a clinical trial for a protein-based COVID-19 vaccine candidate, as pharmaceutical companies race to develop treatments against the coronavirus pandemic.

Sanofi, BMS must face revived whistleblower suit over Plavix marketing

A federal appeals court has revived a whistleblower lawsuit accusing Sanofi-Aventis and Bristol-Myers Squibb of falsely marketing their blood-thinner drug Plavix, finding that a lower court dismissed it based on a misreading of the False Claims Act's "first-to-file" bar.

Sanofi says Kevzara drug fails as possible COVID-19 treatment

The rheumatoid arthritis drug Kevzara has failed as a COVID-19 treatment, French drugmaker Sanofi said on Tuesday following a similar flop of a Roche product.

Sanofi says Kevzara drug fails as possible COVID-19 treatment

French drugmaker Sanofi said on Tuesday its rheumatoid arthritis drug Kevzara - which it produces with partner Regeneron - failed to meet the main goals of a U.S. study testing it in the most critically ill COVID-19 patients.

RPT-EXCLUSIVE-Sanofi more confident about its coronavirus vaccines

Sanofi's confidence in its coronavirus vaccine candidates has increased this summer as the French drugmaker prepares to start clinical trials, its chief executive told Reuters.

Exclusive: Sanofi more confident about its coronavirus vaccines

Sanofi's confidence in its coronavirus vaccine candidates has increased this summer as the French drugmaker prepares to start clinical trials, its chief executive told Reuters.

Translate Bio, Sanofi COVID-19 vaccine candidate produces immune response in animal studies

Translate Bio Inc <TBIO.O> said on Tuesday that an experimental coronavirus vaccine it developed with French drugmaker Sanofi SA <SASY.PA> induced immune response in non-human studies, with trials in humans expected to start in November.

Translate Bio, Sanofi COVID-19 vaccine candidate produces immune response in animal studies

Translate Bio Inc said on Tuesday that an experimental coronavirus vaccine it developed with French drugmaker Sanofi SA induced immune response in early-stage non-human primate studies.

Sanofi in hunt for specialty drugs with $3.7 billion deal for U.S.-based Principia

Sanofi's <SASY.PA> Chief Executive Paul Hudson is dipping into coffers filled by recent disposals to buy U.S.-based Principia Biopharma Inc <PRNB.O> for $3.7 billion as he fills his medicine cabinet with speciality drug prospects from smaller companies.

Breakingviews - Sanofi begins M&A spree with low-risk $3.7 bln bet

Sanofi Chief Executive Paul Hudson is starting a potential M&A spree in a relatively safe fashion. The French drugmaker is buying American biotech Principia Biopharma for $3.7 billion, boosting its presence in the lucrative field of diseases in which the immune system attacks...

U.S. to pay $2.1 billion to Sanofi, GSK, in COVID-19 vaccine deal

The U.S. government will pay $2.1 billion to Sanofi SA and GlaxoSmithKline Plc for COVID-19 vaccines to cover 50 million people and to underwrite the drug makers' testing and manufacturing, the companies said on Friday.

UPDATE 1-U.S. to pay $2.1 bln to Sanofi, GSK, in COVID-19 vaccine deal

The U.S. government will pay $2.1 billion to Sanofi SA and GlaxoSmithKline Plc for COVID-19 vaccines to cover 50 million people and to underwrite the drugmakers' testing and manufacturing, the companies said on Friday.

Sanofi, Glaxo advance talks to supply up to 300 million COVID-19 vaccine doses to Europe: companies

Sanofi SA <SASY.PA> and GlaxoSmithKline Plc <GSK.L> on Friday said they are in advanced discussions with the European Commission to supply up to 300 million doses of the drugmakers's experimental COVID-19 vaccine.

EU in talks to secure Sanofi deal for coronavirus vaccine

Sanofi SA and GlaxoSmithKline Plc on Friday said they are in advanced discussions to supply up to 300 million doses of an experimental COVID-19 vaccine for the 27-country European Union.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up